Abstract 455P
Background
The association of ET and CDK 4/6 inhibitors (CDK 4/6i) is the gold standard of treatment in women with HR+/HER2- MBC. The optimal therapeutic strategy after CDK 4/6i progression is still a matter of debate. The present study aimed to evaluate the benefit of the different treatments adopted in a real-world context.
Methods
In this prospective study we included women with HR+/HER2- MBC progressing to ET plus palbociclib (P). Either ET or chemotherapy (CT) were prescribed taking into account:1) site and burden of disease (visceral/plurimetastatic vs bone only/oligometastatic); 2) median PFS1 (<4 months vs ≥4 months); 3) tolerability profile; 4) patient’s preferences. Primary objective was median progression-free survival 2 (PFS2). Secondary aims: analysis of the determinants of physician’s choice, clinical benefit rate (CBR), impact of neutrophil-to lymphocyte ratio (NLR), monocyte-to lymphocyte ratio (MLR), platelet-to lymphocyte ratio (PLR) and body mass index (BMI) on PFS2.
Results
From May 2017 to October 2021, 78 pre- and postmenopausal patients were enrolled and 56 were evaluable for the final analysis: 18 had received ET plus P as 1st line, 38 in ≥2nd line; 22 patients were excluded because they were still on therapy at the time of the last follow-up. At progression 15 patients (26.7%) received ET (everolimus+exemestane 8, fulvestrant 7) and 41 (73.2%) were treated with CT (eribulin, capecitabine, nab-paclitaxel, vinorelbine). In the whole population mPFS1 was 17.5 months; mPFS2 was 5 months in the overall cohort (95% CI = 4-48 months) with a significant difference between ET and CT (10 months vs 5 months, p=0.035); CBR was 50% and 55.2%, in ET and CT, respectively. At multivariate analysis CT prescription was associated to a higher visceral burden and a shorter mPFS1. Elevated NLR and PLR were correlated with worse PFS2 in both treatment groups, while no impact of MLR and BMI was observed.
Conclusions
In this real life experience, treatments beyond ET plus P failure provided limited but comparable clinical benefit. The physician’s choice was clearly driven by visceral burden of disease; the inflammatory status seems to have a detrimental effect on PFS2.
Clinical trial identification
Ethical Committee number 2295 approved 09.01.2017.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
479P - Radiomics to predict HER2 status in breast cancer brain metastases
Presenter: Gaia Griguolo
Session: Poster session 04
480P - Prognostic significance of somatic DNA gene rearrangement and structural atypia in metastatic breast cancer
Presenter: Hiroshi Tada
Session: Poster session 04
481P - Second generation oral selective estrogen receptor degraders (SERDs) in breast cancer: A systematic review and meta-analysis of clinical trials
Presenter: Maysa Silveira Vilbert
Session: Poster session 04
482P - Precision imaging with human epidermal growth factor receptor 2-positron emission tomography (HER2-PET) for refined treatment selection in patients with HER2-low breast cancer
Presenter: Siri af Burén
Session: Poster session 04
483P - Prognostic value of androgen receptor expression in patients with advanced triple-negative metastatic breast cancer treated with sacituzumab govitecan: A French multicentre retrospective study
Presenter: Monica Arnedos
Session: Poster session 04
484P - Multi-platform characterization of HER2 expression in triple-negative breast cancer
Presenter: Ana C Garrido-Castro
Session: Poster session 04
485P - A novel approach to identify subpopulation of CTCs with metastatic potential using sc-RNA-seq
Presenter: Evgeniya Grigoryeva
Session: Poster session 04
486P - The influence of NF1 germline and somatic mutations on breast cancer patient survival
Presenter: Roope Kallionpää
Session: Poster session 04
487P - Induction of an inflammatory tumor microenvironment with oncolytic virus CF33-hNIS-antiPD-L1 intratumoral injection in patients with metastatic triple-negative breast cancer (mTNBC)
Presenter: Jamie Rand
Session: Poster session 04
488P - Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population
Presenter: Qianyi Lu
Session: Poster session 04